There are 2789 resources available
205P - Immunomodulation in early triple-negative breast cancer (TNBC): Analysis of soluble markers as predictive biomarkers to neoadjuvant chemotherapy in TNBC
Presenter: Martin Nunez Abad
Session: ePoster Display
206P - Disease behavior and treatment response of special histological types of triple-negative breast cancer
Presenter: Renata Bonadio
Session: ePoster Display
207P - Outcomes of patients with triple-negative breast cancer following neoadjuvant chemotherapy with anthracycline and taxane-based regimens plus carboplatin
Presenter: Bryan Vaca Cartagena
Session: ePoster Display
208P - ARB: Phase II window of opportunity study of preoperative treatment with enzalutamide in ER+ve and TNBC
Presenter: Peter Schmid
Session: ePoster Display
249P - The CDK4/6 inhibitors takeover of the HR+/HER2- locally advanced to metastatic breast cancer market in the EU5: Findings from a real-world study
Presenter: Pierre-Olivier Graff
Session: ePoster Display
250P - Palbociclib: Early treatment-related neutropenia as a potential pharmacodynamic marker?
Presenter: Xenia Fernandez Sala
Session: ePoster Display
252P - Does the introduction of CDK4/6 inhibitors (CDKi) in first-line treatment of metastatic breast cancer (MBC) increase medical oncology workload?
Presenter: Claudia Noto
Session: ePoster Display
213P - Predictive markers of cardiotoxicity associated with breast cancer treatment
Presenter: Ines Nogueira Costa
Session: ePoster Display